National Bank of Canada
RVNC

National Bank of Canada’s Revance Therapeutics, Inc. RVNC Stock Holding History

National Bank of Canada’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-954
Closed -$2.9K – 3232
2024
Q4 		$2.9K Buy
954
+22
+2% +$96 ﹤0.01% 2533
2024
Q3 		$4.84K Sell
932
-108
-10% -$537 ﹤0.01% 2219
2024
Q2 		$2.67K Hold
1,040
– – ﹤0.01% 2380
2024
Q1 		$3.44K Hold
1,040
– – ﹤0.01% 2380
2023
Q4 		$9.68K Hold
1,040
– – ﹤0.01% 2176
2023
Q3 		$11.6K Hold
1,040
– – ﹤0.01% 2162
2023
Q2 		$26.3K Hold
1,040
– – ﹤0.01% 1944
2023
Q1 		$33.5K Hold
1,040
– – ﹤0.01% 1832
2022
Q4 		$19.2K Hold
1,040
– – ﹤0.01% 2009
2022
Q3 		$28K Hold
1,040
– – ﹤0.01% 1916
2022
Q2 		$14K Hold
1,040
– – ﹤0.01% 2182
2022
Q1 		$20K Hold
1,040
– – ﹤0.01% 2190
2021
Q4 		$17K Buy
+1,040
New +$17.3K ﹤0.01% 2210

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

National Bank of Canada's RVNC Position: Q1 2025 in Review

National Bank of Canada sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 954 shares — an estimated $2.9K sold.

National Bank of Canada first reported a position in RVNC in Q4 2021 and held it in 13 quarters. The position peaked at $33.5K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • National Bank of Canada reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • National Bank of Canada sold 954 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $2.9K.
  • National Bank of Canada first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 13 quarters.
  • National Bank of Canada's Revance Therapeutics, Inc. position peaked at $33.5K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on National Bank of Canada's 13F filing for Q1 2025, filed 12 May 2025.